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The KRAS GTPase plays a critical role in the control of cellu-
lar growth. The activity of KRAS is regulated by guanine nucle-
otide exchange factors (GEFs), GTPase-activating proteins
(GAPs), and also post-translational modification. Lysine 104 in
KRAScanbemodified byubiquitylation and acetylation, but the
role of this residue in intrinsic KRAS function has not been well
characterized.We find that lysine 104 is important for GEF rec-
ognition, because mutations at this position impaired GEF-me-
diated nucleotide exchange. Because the KRAS K104Q mu-
tant has recently been employed as an acetylationmimetic, we
conducted a series of studies to evaluate its in vitro and cell-
based properties. Herein, we found that KRASK104Q exhibited
defects in both GEF-mediated exchange and GAP-mediated
GTP hydrolysis, consistent with NMR-detected structural per-
turbations in localized regions of KRAS important for recogni-
tion of these regulatory proteins. Despite the partial defect in
both GEF and GAP regulation, KRAS K104Q did not alter
steady-state GTP-bound levels or the ability of the oncogenic
KRAS G12V mutant to cause morphologic transformation of
NIH 3T3 mouse fibroblasts and of WT KRAS to rescue the
growth defect of mouse embryonic fibroblasts deficient in all
Ras genes. We conclude that the KRAS K104Q mutant retains
bothWTandmutant KRAS function, probably due to offsetting
defects in recognition of factors that up-regulate (GEF) and
down-regulate (GAP) RAS activity.
RAS proteins function as molecular switches that cycle
between active GTP- and inactive GDP-bound states to regu-
late signal transduction pathways that modulate cellular
growth control. In the unstimulated cell, RAS proteins are pop-
ulated in their inactive GDP-bound state. However, in response
to growth-stimulatory signals, guanine nucleotide exchange
factors (GEFs)2 co-localize and up-regulate RAS by facilitating
exchange of GDP for GTP. Inactivation of RAS is achieved
through GTPase-activating proteins (GAPs) that bind to GTP-
bound RAS and promote GTP hydrolysis (1, 2). Several point
mutations in RAS have been identified that dysregulate RAS
nucleotide exchange or hydrolysis, often leading to hyperacti-
vation and promoting tumorigenesis. The most common RAS
mutations identified in cancer occur at residues 12, 13, and 61
and render RAS GAP defective, thereby populating RAS in its
active GTP-bound state (3). Constitutive hyperactivation of
RAS promotes chronic stimulation of effector-mediated down-
stream pathways, causing deregulated growth and tumorigenic
growth transformation.
RAS contains two dynamic regions termed switch I (SWI;
residues 30–37) and switch II (SWII; residues 60–76 with
66–74 corresponding to helix 2 (H2)) that populate distinct
conformations when the protein is bound to GDP versus GTP.
Effectors and GAP proteins recognize specific conformations
of the switch regions and bind with preferential affinity to the
active GTP- bound state. Activated GTP-bound RAS can inter-
act with multiple effectors (e.g. RAF kinase, RAL exchange
factors, phosphoinositol 3-kinase (PI3K), the RAC-selective
GEF TIAM1, phospholipase C, NORE1) to promote down-
stream signaling pathways that control cell growth, differenti-
ation, and apoptosis (4).
RAS proteins show high sequence conservation within their
core guanine nucleotide binding domain (G domain) yet pos-
sess a hypervariable C terminus. The hypervariable region
undergoes a variety of post-translational modifications (PTMs)
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that facilitate membrane association and drive differences in
localization and activity (5). Additionally, several lysines within
the core G domain of RAS undergo post-translational modifi-
cations, including acetylation, ubiquitylation, and methylation
(5), but the role of these distinct modifications in regulating
RAS function is still unclear. For example, KRAS monoubiqui-
tylation at lysine 147 up-regulates RAS activity, signaling, and
tumorigenesis (6). Additionally, lysine 104 has been shown to
be aminor site of ubiquitylation, and we have previously shown
that ubiquitylation of KRAS at this position does not alter the
intrinsic biochemical properties or regulation by GEFs and
GAPs (7). In contrast, lysine 104 acetylation was reported to
down-regulate KRAS G12V-driven effector signaling and
growth transformation inNIH 3T3 cells (8, 9).Whereas knock-
down of two deacetylases, HDAC6 and SIRT2, reduced the via-
bility of NIH 3T3 cells expressing the oncogenic KRAS G12V
mutant (9), recent findings indicate that Ac-Lys104 is not a
direct substrate for HDAC6 and SIRT2 under the conditions
tested (10). A KRAS K104Q variant was used as an acetylation
mimetic to evaluate how acetylation alters KRAS signaling.
Molecular dynamics (MD) simulations indicated that theKRAS
K104Qmutation completely disrupts the structural integrity of
H2 (8), consistent with in vitro observations that SOS1-stimu-
lated nucleotide exchange was impaired by 75%. However, the
ability of KRAS K104Q to undergo GAP-stimulated GTP hy-
drolysis was not assessed (8). In NIH 3T3 cells, the K104Q
mutation impaired KRAS G12V-driven effector signaling and
growth transformation (8).
To better understand how perturbations at position 104 of
KRAS alter intrinsic biochemical properties, structure, and reg-
ulatory and effector interactions, we characterizedmutations at
this position, including a K104Q mutant that has previously
been employed as an acetylation mimetic (8). We find that the
K104Q mutation perturbed both GEF- and GAP-stimulated
guanine nucleotide exchange and GTP hydrolysis, respectively,
yet did not alter either CRAF RAS binding domain (RBD) or
PI3K binding. However, in contrast to previous MD predic-
tions, our NMR analyses indicated that KRAS K104Q does not
fully disrupt SWII but rather causes a partial disruption of H2.
Given these observations, we measured the thermal stability
(melting temperature (Tm)) of WT, K104Q and Ac-Lys104
KRAS using circular dichroism (CD). We found that both
K104Q and Ac-Lys104 show amodest decrease in Tm of 1.5 and
3.7 °C, respectively, relative toWT KRAS. Moreover, we found
that K104Q did not significantly impairWT KRAS function, as
measured by the ability to restore growth to Rasless mouse
embryo fibroblasts (MEFs). In slight contrast to a previous
study, we also found that K104Q did not significantly alter
mutant KRAS G12V effector signaling and induction of mor-
phologic transformation. Taken together, our data indicate that
the KRAS K104Q impairs the structural integrity of H2 and
RAS regulation by GEFs and GAPs in vitro but does not signif-
icantly alter the steady-state level of GTP-bound protein in
NIH 3T3 cells. Consistent with our findings that KRAS K104Q
retains effector engagement in vitro and GTP levels in cells, the
K104Q substitution did not significantly alter eitherWTKRAS
or G12V biological activity. We postulate that the conse-
quences of the K104Q substitution onGAP andGEF regulation
probably offset each other to maintain the active GTP-bound
state and effector signaling in cells.
Results
KRAS Lys104 Mutations Disrupt SOScat-mediated Nucleotide
Exchange and p120 GAPcat-mediated Hydrolysis—RAS pro-
teins cycle between inactiveGDP- and activeGTP-bound states
to coordinate downstream signaling and cellular growth. Lysine
104 in KRAS undergoes multiple PTMs, yet the role of this
residue in intrinsic RAS function has not been well character-
ized. In the X-ray structure of KRAS bound to GDP (PDB code
4LPK), the side chain of lysine 104 interacts with the backbone
carbonyl group of Arg73 and Gly75 contained within SWII. Dis-
ruption of these interactions has been proposed to perturb the
structural integrity of SWII and alter interactions with regula-
tory proteins and effectors that interact with SWII (11, 12).
Moreover, Arg102 and Val103, surrounding Lys104 in H3, inter-
act directly with the SOS catalytic domain (PDB code 1NVW)
(13). Hence,mutations or PTMs that perturb these interactions
may prevent proper SOS-mediated up-regulation of RAS.
Consistent with these observations, it has been shown previ-
ously that KRAS K104Q disrupts SOScat-mediated nucleotide
exchange (8). KRAS K104Q has been dubbed an acetylation
mimetic, yet how this mutation affects the structure of RAS,
GAP-mediated GTP hydrolysis, and effector recognition has
not been determined. To further investigate the role of non-
conservative and conservative mutations at this key position,
we mutated residue Lys104 to glutamine, arginine, and alanine
andmonitored the rate ofMANT-GDP nucleotide dissociation
in the absence and presence of SOScat. As shown in Fig. 1A, all
three mutations impaired SOS-mediated nucleotide exchange.
In particular, a reduction in the rate ofGDPdissociation by 78%
for K104Q, 75% for K104R, and 50% for K104Awas observed in
comparison with WT KRAS (12.5  0.2  104 s1) (Fig. 1A
and Table 1). All three mutations, even the K104R variant that
retains the side chain positive charge, impaired SOS-mediated
exchange. AlthoughKRASK104R has previously been reported
to retain GEF activity (8), we find that this conservative substi-
tution (K104R) impaired SOS regulation of RAS nucleotide
exchange. These findings indicate that Lys104 plays an essential
role in SOScat-mediated nucleotide exchange of KRAS. Because
the K104Q variant was predicted to impair the structural integ-
rity of SWII (8), which is also important for GAP-mediated
down-regulation of RAS activity, we measured both the intrin-
sic and GAP-mediated rate of GTP hydrolysis (Table 1).
Although the intrinsic rate of GTP hydrolysis for KRAS K104Q
is similar to that ofWTKRAS, we found a significant reduction
(53%) in the p120 GAPcat-stimulated rate of GTP hydrolysis
(Fig. 1B). Taken together, these data suggest that the K104Q
mutation, which has been used as a RAS acetylation mimic,
impairs regulation of GDP/GTP cycling by both GEFs and
GAPs.
Upon GEF-mediated GDP exchange for GTP, RAS-GTP
undergoes a conformational change in both the SWI and SWII
regions. This in turn promotes binding to downstreameffectors
(14). Although SWI is a primary binding site for a subset of
RBDs (i.e. RAF and RALGEFs), some effectors (i.e. PI3K, PLC,
and NORE1) bind to RAS using both SWI and SWII regions
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(14). To assess whether the K104Qmutation alters KRAS effec-
tor interactions, we determined the binding affinity of KRAS
K104Q to the RAS RBDs of CRAF and BRAF as well as PI3K,
by monitoring the dissociation rate of MANT-GMPPCP as
function of RAS effector concentration (Table 1). Results from
these analyses indicate that KRAS K104Q retains binding to
RAF RBDs and PI3K relative to WT RAS (Fig. 1C).
The KRAS K104Q and Ac-Lys104 Decrease Thermal Stability—
To evaluate the effects of side chain modification at Lys104 on
thermal stability, we measured the Tm for His6-WT KRAS,
K104Q, and Ac-Lys104 by CD, by monitoring the thermal tran-
sition as a function of temperature, as shown in Fig. 2A. We
found that K104Q and Ac-Lys104 KRAS showed similar coop-
erative unfolding transitions but possessed a lower Tm (K104Q
(64.2  0.1 °C), Ac-Lys104 (62.0  0.5 °C)) in comparison with
WTKRAS (65.8 0.4 °C). The small Tm changes shown in Fig.
2B indicate that acetylation ormutation of the Lys104 side chain
alters protein stability.
The KRAS K104Q Mutation Perturbs the Conformation of
Helix 2 and Helix 3—Given the decrease in protein stability
observed for KRAS K104Q, we conducted NMR studies to
investigate whether the mutation alters KRAS structure. The
RAS switch regions undergo distinct conformations when
bound to either GDP or GTP. These conformational changes
are key to recognition of GAPs and effector proteins as well as
GTP-dependent SOS allosteric regulation (15). Based on the
crystal structure of KRAS bound to GDP (PDB code 4LPK), the
Lys104 amino side chain interacts with the backbone carbonyls
of Arg-73 and Gly-75 located at the end of SWII (see Fig. 5A).
These interactions were previously predicted to play a key role
in the structural integrity of SWII, because MD simulations
suggested that both the KRAS K104Q mutation and Lys104
acetylation cause complete disruption of H2 within SWII (8).
However, given our findings that KRASK104Q retains the abil-
ity to hydrolyze GTP (Fig. 1B), it is unlikely that helix 2 under-
goes a full helix-coil transition upon mutation or acetylation.
To better address this apparent discrepancy, we employed
NMR spectroscopy to characterize structural and dynamic
changes in KRAS upon mutation of lysine 104 to a glutamine.
We first assigned the backbone resonances ofWT andKRAS
K104Q bound to Mg2 and GDP by acquiring a series of triple
resonance NMR experiments on 13C,15N-enriched KRAS
1–169 (16). We were able to assign 159 and 161 of 167 non-
proline backbone NH, C, and C resonances for WT and
KRAS K104Q, respectively. A 2D 1H-15N heteronuclear single
quantum coherence (HSQC) spectral overlay of K104Q and
WT KRAS bound to GDP is shown in Fig. 3. 1H-15N HSQC
spectra allow for the detection of protons directly bonded to a
15N, including both backbone and side chain NH resonances.
Because an NH resonance can be detected for every residue
FIGURE 1. The KRAS K104Qmutation impairs regulation by GEFs and GAPs yet retains effector binding interactions with RAF and PI3K RAS binding
domains. A, E. coli-expressed and purified WT and mutant (K104Q, K104R, and K104A) were loaded with MANT-GDP, and the rate of GDP dissociation was
determined by monitoring the decrease in MANT-GDP fluorescence emission over time in the absence and presence of an SOS (Ras/SOScat 1:1). Data were
fit to an exponential dissociation curve. Rates are reported as themean S.E. (error bars) (n 2). B, p120GAPcat-mediatedGTP hydrolysis, as determined using
single-turnover GTP hydrolysis for KRASWT and K104Q in the absence or presence of p120 GAP (GAPcat/Ras 1:200). Hydrolysis was initiated by the addition
of Mg2 andmonitored by the change in fluorescence of the protein, Flippi, upon binding free phosphate. Data were converted to phosphate concentration
using a standard curve. Results are the mean  S.E. (n  2). C, the binding affinity of KRAS WT and K104Q to CRAF RBD, BRAF RBD, and PI3K K802T was
determined by loading KRAS proteins with MANT-GMPPCP and measuring nucleotide release rates as a function of effector protein concentration. To
determine the affinity (KD) for the KRAS-effector complex, the data were fitted to a standard curve. Relative binding affinity to KRASWT is shownwith original
values included in Table 1. Results are reported as the mean S.E. (n 2). All of the original values are listed in Table 1.
TABLE 1
Biochemical properties of WT and KRas 104mutants
Property WT K104Q K104R K104A
Nucleotide exchange
rate (104 s1)
Intrinsic 2.0 0.1 1.2 0.1 1.4 0.1 1.2 0.1
SOScat 12.5 0.2 2.8 0.1 3.2 0.1 6.3 0.1
GTP hydrolysis
rate (103 s1)
Intrinsic 0.1 0.1 0.1 0.1
p120 GAPcat 7.6 0.5 3.6 0.2
Effector affinity
(KD) (M)
BRAF RBD 0.2 0.1 0.1 0.02
CRAF RBD 0.2 0.1 0.2 0.1
PI3K (p110
subunit, K802T)
16.2 6.1 17.2 1.2
FIGURE 2. Ac-Lys104 and K104Q KRAS show decreased thermal stability
relative toWTKRAS.A, the CD signal at 222 nmwasmonitored as a function
of temperature (20–95 °C) for His6-WT KRAS, K104Q, and Ac-Lys
104 (20 M)
bound to GDP. B, themidpoint of the thermal transition (Tm) was determined
by fitting the temperature dependence in A. Results are reported as the
mean S.E. (error bars) (n 3).
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with the exception of proline, the spectrum contains a “finger-
print” of the protein backbone. Inspection of chemical shift
differences between KRAS WT and K104Q bound to GDP
show that30% of the backboneNHpeaks undergo changes in
peak position.Using chemical shift perturbation (CSP) analyses
(Fig. 4A), we found that the largest CSPs (	0.2 ppm) corre-
sponded to residues proximal to the site of the mutation (posi-
tions 102–110) and within SWII. Smaller (
0.2 ppm) CSPs
were observed for residues within the first -sheet. In contrast,
residues in SWI do not show significant CSPs. These findings
are consistent with perturbation of contacts between Lys104,
Arg73, andGly75 at the end of SWII due tomutation of Lys104 to
glutamine.
Because a comparison of C and C chemical shifts can be
used to evaluate differences in secondary structure (17), we
employed chemical shift indexing (CSI) to compare secondary
structural differences between K104Q andWTKRAS (Fig. 4B).
We found that overall, the secondary structure of WT KRAS is
similar to K104Q with the exception of H2 and H3. In contrast
to MD predictions that KRAS K104Q completely disrupts the
structural integrity of the SWII region, CSI analyses (Fig. 4C)
indicate loss of secondary structure for residues 70–74 at the
C-terminal end of H2 and loss of helical content for residues
102–103 in helix 3 (H3) near the mutation site (Fig. 4B), which
is consistent with the Tm decrease observed for K104Q. These
secondary structural changes correlate with the large CSP
observed for these residues (Fig. 4A). The perturbed regions
revealed by NMR are highlighted in the 3D structure (Fig. 5B).
Small distortions in secondary structure were also observed for
the first half of SWII, 1, and the loop between SWI and SWII.
However, SWI is unperturbed, consistentwith our findings that
binding of K104Q to effector RBDs is retained (Fig. 1C).
We also collected backbone NH residual dipolar coupling
(RDC) data to generate long range distance constraints and
evaluate changes in tertiary structure. As shown in Fig. 4D,
comparison of the RDC profile forWT and KRAS K104Q indi-
cates that the K104Q mutation does not significantly alter the
overall tertiary structure of KRAS.
The KRAS K104Q Shows Backbone Dynamics Similar to
Those of WT KRAS—The switch regions of RAS have been
shown to samplemultiple conformations in both the GDP- and
GTP-bound states, as revealed by NMR (18–20). Conforma-
tional dynamic properties of these key regions are important for
recognition of regulatory and effector proteins. Given the dis-
FIGURE 3. 2D 1H-15N HSQC NMR spectral overlay of 15N-enriched KRAS
K104Q (red) and WT (blue). Residues that show significant chemical shift
perturbations (CSP 	 0.15) are marked. Spectra were recorded on a Bruker
Avance III 700 at 25 °C using 0.7mMKRASWT and KRAS K104Qbound to GDP.
FIGURE 4. K104Q causes structural and dynamic perturbations primarily
in helix 2 and helix 3. A, NMR analyses of peak shifts reveal that the K104Q
mutation causes large CSPs in switch II and residues 102–110 in helix 3 but
minor changes in 1 and switch I. CSP was calculated based on weighted
average chemical shift (square root of (( 1H)2 ( 15N)2/25)) of WT and
K104Q KRAS NH peaks in 1H-15N 2D HSQC NMR spectra. B, differences in
secondary structure were determined from C and C chemical shift index-
ing. C, the difference in chemical shift indexing between K104Q andWTKRAS
indicates that the KRAS K104Qmutation perturbs the local conformation sur-
rounding104 inH3and the later part of the2helix (residues71–74) in switch
II. D, NH RDCs were obtained from alignment in Pf1 bacteriophage with deu-
terium splitting of15 Hz. Switch I, switch II, and H3 are highlighted in pink
(ribbon). NMR spectrawere recorded at 25 °ConKRASWTandK104Q (0.7mM)
bound to GDP using a Bruker Avance III 700 NMR spectrometer.
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ruption in secondary structure within SWII, we evaluated
whether theK104Qmutation alters backbonedynamic properties
of KRAS, in the absence of regulatory proteins or effectors. We
collected spin relaxation parameters R1 (Fig. 6A), R2 (Fig. 6B),
and 15N-(1H) NOE (Fig. 6C) and fit them to spectral density
functions for obtaining order parameters (21). The order
parameter S2 provides a measure of restriction of motion over
the picosecond to nanosecond range; whereas S2  1 suggests
that the NH vector is rigidly fixed in the molecular frame, S2
0 is indicative of high mobility. Consistent with an increase in
backbone motion due to structural perturbations at residues
proximal to the site of mutation and the C-terminal end of H2,
reduced S2 values were observed in the loop (positions 104–
107) between H3 and 5 (Fig. 6D) as well as for residues 72–73
in SWII. A smaller decrease in S2 is observed for residues in
SWI. We also observed that the K104Q mutation slightly
enhances fast time scale backbonemotions for the loop preced-
ing H2 and residues 94–96 in H3. Taken together, these obser-
vations are consistent with our findings that H2 and H3
undergo small scale structural distortions and that the altered
GEF and GAP activities observed for KRAS K104Q are proba-
bly due to changes in protein structure rather than the altered
switch dynamics.
KRAS K104Q Does Not Affect Growth in MEFs—Because the
KRAS K104Q mutation is impaired in GEF/GAP-mediated
nucleotide cycling yet retains the ability to bind the RAF RBDs
and PI3K, we conducted studies in cell culture to determine
the role of the K104Q mutation in KRAS-driven cellular
growth. For these studies, we employed the use of Rasless
MEFs, which lack endogenousHras andNras, and a conditional
Kras allele that can be ablated by activation of a knocked-in
4-hydroxytamoxifen-inducible CreERT2 recombinase (22).
4-Hydroxytamoxifen treatment was done to induce Cre-medi-
ated disruption of theKras allele with blotting analyses to verify
loss of endogenous Kras protein expression (Fig. 7A). These
viable but non-proliferating cells were then used to assess the
ability of either WT KRAS or KRAS K104Q to rescue loss of
endogenous Kras and restore proliferation.We found that both
K104Q andWTKRASwere equally capable of promotingMEF
proliferation, as assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) growth assays (Fig. 7, B
and C). These results suggest that KRAS acetylation may not
impair the ability of KRAS to drive growth in a KRAS-depen-
dent system. Based on our findings that K104Q is impaired in
bothGEF andGAP regulation, the disruption inGEF-mediated
up-regulation by the K104Qmutationmay be partially offset by
a defect in GAP-mediated down-regulation of KRAS. Our find-
ings that KRAS K104Q supports the growth of Rasless MEFs
indicate that this mutant can still efficiently activate the RAF-
MEK-ERK pathway, because this pathway is critical for the
growth of Rasless MEFs (22).
TheKRASK104QVariant Retains RASActivity, Downstream
Signaling to Critical KRAS Effectors, and KRAS-driven Trans-
formation in NIH 3T3 Cells—We next assessed the conse-
quences of the K104Q substitution for the cellular activity of
WT and G12V KRAS when transiently expressed in NIH 3T3
mouse fibroblasts. First, we performed a RAF-RBD pull-down
analysis to assess the relative steady-state levels of activated
GTP-bound KRAS protein. The K104Q substitution did not
significantly alter the low level of GTP-bound protein for WT
KRAS or the elevated level for KRAS G12V (Fig. 8). Similarly,
KRAS G12V- and KRAS G12V/K104Q-expressing cells exhib-
ited comparable levels of effector signaling, with equivalent lev-
els of phosphorylated and activated ERK and AKT (Fig. 9) and
morphologic transformation (Fig. 10).We conclude that muta-
tion of Lys104 to glutamine (a putative acetylation mimetic) did
not significantly alter KRAS function.
Discussion
Whereas GEF and GAP proteins play a critical role in regu-
lating the activation state of RAS proteins, post-translational
modifications within the G domain of RAS add another level of
FIGURE 5.The side chain of Lys104 in helix 3 interactswithhelix 2 in switch II.A, expanded region illustrating interactions betweenH3 andH2, derived from
the X-ray structure of KRAS-GDP (PDB 4LPK, resolution 1.5 Å). Hydrogen atomswere added to structure using XLeap (Amber). The Lys104 amino side chain is in
close proximity to backbone carbonyl oxygens of Arg73 (H2) andGly75 in switch II. B, structural perturbations revealed byNMR aremapped on the 3D structure
(PDB code 4LPK). Switch I and switch II are coloredwith pink and purple, respectively. Lys104 is represented by spheres. The perturbed regions, as determined by
NMR-derivedCSPandchemical indexing, arehighlighted in red for the latter part of theH2and the2-4 loop (residues71–76) and yellow for residues102–103
in H3.
KRAS K104Q Retains Downstream Signaling
4450 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 11•MARCH 17, 2017
complexity. Lysine 104 in KRAS undergoes multiple PTMs,
including acetylation (8) and ubiquitylation (23). Because onco-
genic mutations at this position have not been identified in H-,
N-, or KRAS, the role of this key residue has not been well
characterized. Here, we show that both conservative and non-
conservative mutations at KRAS lysine 104 (Gln, Arg, and Ala)
impair SOScat-mediated nucleotide exchange. The K104Q
mutant also impairs p120 RASGAPcat-mediated GTP hydroly-
sis. Consistent with these observations and our findings that
KRAS K104Q shows a small decrease in thermal stability
(1.5 °C), NMR structural analysis indicates that the K104Q
mutation perturbs protein conformation proximal to the site of
mutation in H3 as well as the end of H2 in SWII. Both of these
regions are part of the RAS/SOScat binding interface (13). Res-
FIGURE 6.Backbone 15N relaxationparameters for K104QKRAS (red) andWTKRAS (blue). Shown from top to bottom, plotted against residue number, are
longitudinal relaxation R1 (A), transverse relaxation R2 (B), (
1H)-15N steady state heteronuclear NOE (Isaturated/Iunsaturated) (C), and order parameter S
2 (D). Switch
I, switch II, and H3 are highlighted in pink (ribbon) with secondary structure content represented at the top. Residue 104 at the end of H3 is labeled in red. All
measurementswereperformedonKRASWTandK104Qbound toGDP.NMRdatawere collectedat 25 °Con0.2mMKRASWTandK104QsamplesusingaBruker
Avance III 700 NMR spectrometer.
FIGURE 7. Exogenous KRAS K104Q expression supports the growth of Rasless MEFs. A, the anchorage-dependent growth rate was determined for MEFs
deficient for all Ras isoforms with ectopically expressed KRAS WT or K104Q. B, cells were plated, and growth was monitored at days 1, 4, and 7 using the MTT
viability assay. Data shown are representative of two independent experiments. Data are themean S.D. (error bars) (n 48). Student’s t test determined that
the difference was not significant (NS). C, quantitation of the average S.D. of three independent experiments for day 7. Data shown are the average of three
independent experiments.
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idues 61–64 and 67 in SWII also formbinding interactionswith
RAS GAPcat (24).
Residues within H2 and H3 of RAS form multiple interac-
tions with SOS1cat in crystal structures of RAS proteins bound
to SOS1 (PDB codes 1BKD, 1NVW, and 1XD2) (13, 25, 26). In
particular, Arg102 in H3, next to the mutation site, forms con-
tactswith Phe1010 andAsp1007 in SOScat. Valine 103 inH3 inter-
acts with Ser881 in SOScat. Moreover, residues Gln70, Tyr71, and
Arg73 at the end of H2 in RAS form multiple binding interac-
tions with SOScat (27). Specifically, Tyr71 forms a hydrogen
bond with Tyr912 of SOScat. Additionally, the side chain of
Arg73 forms a hydrogen bond with the carboxyl oxygen of
Asn879, and its aliphatic side chain forms additional interac-
tions with the aromatic ring of Tyr884 in SOScat. Thus, struc-
tural distortions due to either mutation or PTM in H2 could
potentially impair binding interactions to SOScat. Given the
structural distortions observed for residues in SWII and H3, it
is not surprising that binding to and subsequent nucleotide
exchange ability of SOScat is impaired by the K104Q mutation
(13, 27). In addition to SOS, residues in SWII, including Glu63
and Tyr64, make multiple contacts with RAS GAP proteins
(PDB code 1WQ1) (24). Structural distortions at the end of
SWII may cause more subtle changes in these key residues,
resulting in the partial disruption of GAP-mediated GTP hy-
drolysis, observed for KRAS K104Q.
Consistent with our findings that the structure of the KRAS
SWI region is not perturbed by the K104Qmutation, the KRAS
K104Q mutant shows similar binding to isolated RAS effector
RBDs, such asCRAF andBRAF,which bind exclusively through
SWI (PDB code 4GON). A distinct effector, PI3K, interacts
with RAS primarily at SWI but also forms additional contacts
with Tyr64 and Arg73 in SWII (PDB code 1HE8). Despite the
structural perturbations induced by theKRASK104Qmutation
in the SWII region, KRAS K104Q retains binding to PI3K.
Whereas RAS interacts with a number of downstream effectors
to regulate cellular growth, our analyses in Rasless MEFs indi-
cate that the K104Q substitution does not prevent KRAS WT
from driving proliferation in this biological context. Further-
more, our analyses in NIH 3T3 cells indicate that K104Q did
not significantly alter the steady-state GTP-bound state or
effector signaling and activation of ERK or AKT. These studies
also indicate that KRAS G12V/K104Q is equally capable of
drivingmorphologic transformation inNIH3T3 cells. Hence, if
K104Q functions as an acetylation mimetic, our studies indi-
cate that this PTM may not significantly impair mutant RAS
oncogenic function in these cells. Our findings differ from
those described previously (8), where K104Q did reduce KRAS
G12V stimulation of NIH 3T3 cell proliferation. Because these
analyses evaluated morphologic and not growth transforma-
tion, our results cannot be directly compared with those of the
previous study. One possible explanation for our different con-
clusions is that there exist multiple strains of NIH 3T3 cells and
there are strain-specific differences in the mechanisms by
which RAS drives growth transformation (28).
In summary, we found that the K104Q mutation in KRAS
impaired GEF and GAP regulation but retained interactions
withRAF andPI3KRBDs.Our observations that signaling and
cellular growth properties of K104Q are similar to those ofWT
KRAS suggest that the partial defect in GEF is at least partially
offset by a defect inGAP regulation to retain RAS signaling. It is
unclear whether the K104Q mutation or acetylation at this
position perturbs interactions with all RAS GEFs. Whereas the
CDC25 domains associated with RASGRP and RASGRF pro-
teins showhigh homology (29, 30), allosteric regulation of these
GEFs is quite distinct from that of SOS1. Moreover, crystal
structures of these GEFs in complex with RAS are lacking.
Given the difficulties in preparation of various protein PTMs,
mutations are often used as reagents to eithermimic the desired
modification or prevent the PTM. Although K104Q has been
employed as an acetylation mimetic, this has yet to be truly
validated. In fact, Lys104 acetylation has recently been reported
FIGURE 8. The K104Q mutation does not alter the levels of GTP-bound
KRAS. CRAF RBD pull-down analyses were done using cell lysates from NIH
3T3 cells transiently expressing (72 h post-infection) the indicated HA
epitope-tagged KRAS WT or mutant proteins. GST-CRAF RBD was used to
monitor the level of GTP-bound KRAS protein, with total expression deter-
mined by anti-HA blot of total cellular lysates. Data shown are representative
of three independent experiments. Quantitation of three experiments done
in A (n 3), with KRAS-GTP levels normalized to total HA-tagged KRAS levels.
Error bars, S.E. Student’s t test determined that the difference was not signif-
icant (NS).
FIGURE 9. The K104Qmutation does not alter KRAS effector signaling in
NIH 3T3 cells. Shown is Western blotting analysis of total cell lysates from
mass populations of NIH 3T3 cells transiently infected (72 h) with retrovirus
expression vectors encoding the indicated KRAS proteins. Blotting analyses
with antibodies for total or phosphorylated and activated AKT and ERK (pAKT
and pERK, respectively) were done. Data shown are representative of three
independent experiments.
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to retain SOS activity (10). Computational analysis of the Ku
protein revealed that acetylation of the Ku may not alter DNA
interaction, yet a K-to-Qmutation decreased the binding com-
pared with the WT protein (31). Indeed, the side chain of glu-
tamine is quite distinct from an acetylated lysine in both size
and composition, and it is unlikely that the K104Qmutant will
be recognized by acetylation readers or deacetylases, such as
SIRT2 and HDAC6, in a similar manner to native acetylated
RAS (9). Although emerging data indicate that Lys-to-Gln
mutations may not fully mimic acetylation, our studies do indi-
cate that Lys104, a hot spot for RAS PTMs, plays a key role in
maintaining the structural integrity of H3 and H2. Given the
proposed role of H3 in RAS-mediated dimerization at the
membrane, it is possible that KRAS acetylation may alter RAS
dimerization (32). It will be important to evaluate each PTM
(acetylation, ubiquitylation) separately to determine how the
PTM may directly alter RAS activity as well as protein-protein
interactions.
Experimental Procedures
Protein Expression and Purification—The human KRAS4B
(C118S) cDNA sequence encoding the G domain (residues
1–169) was subcloned into a pET21 vector that adds an N-ter-
minal 6-histidine tag and a TEV protease cleavage site for
expression of recombinant protein in Escherichia coli BL21(DE3)
cells (Novagen). Standard site-directed mutagenesis tech-
niques were used to generate KRAS cDNA sequences encod-
ing K104Q, K104A, and K104R missense mutants. The muta-
tions were subsequently verified by DNA sequencing. E. coli
BL21 (DE3) cells were grown at 37 °C in Luria-Bertani (LB)
medium supplemented with ampicillin and chloramphenicol
until A600 of0.5. The temperature was then lowered to 18 °C,
and KRAS expression was induced with 0.5 mM isopropyl--D-
1-thiogalactopyranoside (IPTG) after 30 min. The cells were
grown for an additional 15 h at 18 °C. The cells were then har-
vested and pelleted at 4000 rpm, resuspended in a lysis buffer
(20 mM HEPES, 500 mM NaCl, 1 mM MgCl2, 20 mM imidazole,
5% glycerol (pH 7.75), and protease inhibitor phenylmethane-
sulfonyl fluoride (ACROS Organics)), and sonicated. The cell
lysate was centrifuged at 15,000 rpm, and the supernatant was
isolated. KRAS proteins were purified using nickel-nitrilotri-
acetic acid-agarose affinity chromatography (Qiagen), and the
histidine tag was cleaved during overnight dialysis using TEV
protease. If needed, KRASproteinswere further purified by size
exclusion chromatography using a Sephadex G-75 column.
Protein purity of 	95% was obtained and verified by SDS-
PAGE analysis.
The catalytic domains of human SOS1 (SOScat, residues
566–1049) (26) and p120-RASGAP (GAPcat, residues 764–
981) were expressed in a pQlinkH vector (Addgene) and puri-
fied as described previously (33). cDNA sequences encoding
the isolated RBDs of human BRAF (amino acids 149–232) and
CRAF (amino acids 51–132) were subcloned in a pET28a bac-
terial expression vector encoding an N-terminal 6-histidine tag
and TEV cleavage sites and subsequently expressed in BL21
(DE3) cells. The RBDs were purified using nickel-nitrilotri-
acetic acid affinity chromatography. The N-terminal tags were
cleaved overnight with TEV protease. The tagless BRAF RBD
was further purified using size exclusion chromatography (Sep-
hadex G-75) and verified to be	95% pure by SDS-PAGE anal-
ysis. Purified PI3K protein (amino acids 144–1102) contain-
ing a K802T substitution was kindly provided by Genentech.
Expression and Purification of His6-WT KRAS, K104Q, and
Ac-Lys104 Proteins—His6-WT KRAS (residues 1–169, contain-
ing a 12-amino acid N-terminal non-cleavable His6 tag) and
K104Q were expressed in LB medium as His6-tagged fusion
proteins (pRSF-Duet, Merck Biosciences) in E. coli BL21 (DE3)
cells as described (10). The E. coli culture was grown to an A600
of 0.6 (37 °C; 160 rpm), and protein expression was subse-
quently induced by the addition of 300 M IPTG and further
incubated overnight for 16 h (18 °C, 160 rpm). KRAS containing
an amber stop codon at Lys104, was co-expressed with a pRSF-
Duet-1 vector containing the synthetically evolved Methano-
sarcina barkeriMS tRNACUA (MbtRNACUA)/acetyl-lysyl-tRNA-
synthetase (pAcKRS3) pair in Terrific broth medium. The
E. coli BL21 (DE3) KRAS Ac-Lys104 culture was grown to an
A600 of 0.6 at 37 °C at 160 rpm and then supplementedwith 10
FIGURE 10. The K104Qmutation does not alter wild type or activated KRAS morphologic transforming activity. Shown is a photomicrograph of mass
populations of NIH 3T3 cells transiently (24 h) infected with pBabe-puro retrovirus expression vectors encoding the indicated KRAS proteins.
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mM N-()-acetyl-lysine (Chem-Impex International Inc.) and
20mMnicotinamide to inhibit theE. colideacetylaseCobB. The
temperature was then reduced to 18 °C. After 30 min, protein
expression was induced by the addition of 300 M IPTG. The
cells were then grown for 16 h at 20 °C.
After expression, the cells were harvested (4000 g, 20 min)
and resuspended in a buffer containing 50 mM Tris/HCl, pH
7.4, 100 mMNaCl, 5 mMMgCl2, 2 mM -mercaptoethanol, and
200MPefabloc protease inhibitormixture forHis6-WTKRAS
and K104Q. For His6-KRAS Ac-Lys104, a buffer containing 50
mMK2HPO4/KH2PO4, pH6.4,was used. The cellswere lysed by
sonication, and the soluble fraction (20,000  g, 45 min) was
applied to an equilibrated Ni2-nitrilotriacetic acid affinity
chromatography column. The column was washed with a
buffer containing 10 mM imidazole and 1 M NaCl, pH 6.4. The
His6-KRAS proteins were eluted with an imidazole gradient of
10 columnvolumes covering 10–500mM imidazole. The pro-
teinwas concentrated by ultrafiltration and applied to aHiLoad
16/600 Superdex 75 pg size exclusion chromatography column
(GE Healthcare).
RAS Nucleotide Dissociation and Hydrolysis Assays—The
rate of nucleotide dissociationwasmeasured by a fluorescence-
based assay using MANT-GDP (BioLog, San Diego, CA) as
reported previously (34, 35). Briefly, MANT-GDP-bound RAS
was added to 1 ml of assay buffer (20 mM HEPES, 50 mM NaCl,
5 mM MgCl2, and 100 M diethylenetriaminepentaacetic acid
(DTPA), pH 7.4) to a final concentration of 1 M, and nucleo-
tide exchange was initiated by the addition of 1 mM GDP.
MANT-GDP dissociation wasmeasured as a change in fluores-
cence intensity over time (excitation, 365 nm; emission, 435
nm) (LS50B PerkinElmer Life Sciences luminescence spec-
trometer). Fluorescence data were fit in GraphPad Prism
(GraphPad Software, La Jolla, CA) to a one-phase exponential
decay curve. For GEF-mediated dissociation, 1 M RAS and 1
M SOScat were used. Results are plotted as the mean  S.E.
(n 3).
Single-turnover GTP hydrolysis assays were performed as
described previously (36) using the phosphate-binding protein
Flippi 5U (Addgene) to detect inorganic phosphate released
upon GTP hydrolysis (37). Flippi 5U was purified as described
previously (37). All buffers were made phosphate-free by dial-
ysis with 1 unit of nucleoside phosphorylase (Sigma) and 2 mM
inosine (Sigma). For GAP-mediated hydrolysis, 10MRASwas
used with 0.05 M p120-RASGAPcat (1:200). The ratio of fluo-
rescence emission was measured at 485 and 530 nm with an
excitation of 420 nm on a SpectraMax M5 microplate reader
(Molecular Devices). Hydrolysis curves were fit in GraphPad
Prism to a one-phase exponential association curve. Results are
plotted as the mean S.E. (n 2).
Effector Binding Assay—KRAS was preloaded with MANT-
GMPPCP using methods described previously (38). For quan-
titative binding to CRAF and BRAF RBDs and PI3K (amino
acids 144–1102, containing a K802T substitution), MANT-
GMPPCP-boundKRASwas incubatedwith the desired effector
at a range of concentrations, in a buffer containing 50 mM
HEPES, 50 mM NaCl, and 5 mM MgCl2 at pH 7.4. Nucleotide
dissociation was initiated by the addition of a 1000-fold molar
excess of unlabeled nucleotide, and the rate of dissociation was
determined by monitoring the change in fluorescence of the
MANT-GMPPCP-loaded protein (excitation and emission
wavelengths of 335 and 485 nm, respectively) using a Spectra-
Max M2 plate reader (34). Each nucleotide dissociation curve
was fit to a one-phase single exponential to determine kobs. The
dissociation rates were plotted against the effector concentra-
tions and fit as described previously (39) to determine the equi-
librium dissociation constant (KD).
Tm Measurements Using CD—CD data were collected on a
Jasco J-815 CD spectrometer. Far-UV CD scans were collected
using a 1-mmcuvette at a concentration of 20MKRASprotein
in a buffer containing 10 mM KH2PO43/K2HPO43, 500 M
MgSO4, pH 7.2, at 20 °C. Thermal melts were obtained over a
temperature range of 20–95 °C using a temperature increment
of 2 °C/min. The CD signal was measured at 222 nm. Tm values
were calculated by fitting the thermal denaturation data using
non-linear fitting. Results are plotted as the mean  S.D.
(n  3).
NMR Analyses—For NMRmeasurements, 13C,15N-enriched
KRAS proteins were exchanged into NMR buffer (20 mM Tris-
maleate (pH 6.5), 40 mM NaCl, 5 mM MgCl2, and 20 M GDP,
5% D2O). NMR spectra were acquired at 25 °C on a Bruker
Avance III 700 NMR spectrometer. 2D 1H-15N HSQC experi-
ments were recorded for bothWT and K104Q KRAS bound to
GDP, with 1024 and 256 complex points in the direct and indi-
rect dimensions, respectively, 32 scans/increment, and a recov-
ery delay of 1.0 s. Spectral widths used were 9803.992 Hz (1H)
and 2553.626 (15N) Hz. Average 1H-15N chemical shift per-
turbations were calculated according to the square root of
(( 1H)2  ( 15N)2/25), where  1H and  15N are the
observed changes in 1H and 15N chemical shifts.
Backbone resonance assignments of WT KRAS were ob-
tained by analysis of 3D HNCA, HNCACB, CBCA(CO)NH,
HNCO, and HN(CO)CA spectra recorded on 13C,15N-labeled
WT KRAS bound to GDP. The assignment of C, C, CO, N,
and HN chemical shifts was obtained by an iterative procedure
using the program MARS (40) and manual inspection. Back-
bone assignment of 13C,15N-enriched K104Q KRAS (0.8 mM)
was obtained by collecting 3D HNCA and HNCACB data and
using WT KRAS assignments. For CSI, C and C values
were calculated by subtracting experimental chemical shifts of
C and C from random coil values obtained from the ncIDP
server (41). The value ofC-Cwas calculated to cancel the
systematic offset contained in C and C and then used to
predict RAS secondary structure. For 15N-based backbone
relaxation experiments, 15N longitudinal (R1) and transverse
relaxation (R2) rates and 1H-15N steady-state NOE were mea-
sured on 200 M 15N WT and K104Q KRAS-GDP samples in
NMR buffer at 700 MHz. Relaxation delays were as follows: R1
measurements, 0.01, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.0, 1.2, and 1.4 s;
R2 experiments, 15.01, 45.03, 165.11, 30.02, 135.09, 60.04,
105.07, 75.05, and 90.06 ms. The 15N-(1H) NOE and reference
spectra were recorded in an interleavedmanner with a 5.5-s 1H
saturation time and the equivalent recovery time for the refer-
ence experiment. Order parameters (S2) were calculated by fit-
ting relaxation parameters R1, R2, and 15N-(1H) NOE using the
programs FASTModelFree (42) andModelFree (43). Backbone
NH RDCs were measured using Pf1 bacteriophage (20 mg/ml)
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(ASLA Biotech) with deuterium splitting of 15 Hz. The 1JNH
constant was measured using an interleaved HSQC-TROSY.
Spectra were processed and analyzed usingNMRPipe (NIDDK,
National Institutes of Health) and Sparky (University of Cali-
fornia, San Francisco).
Cell Lines—NIH 3T3 mouse fibroblasts were obtained origi-
nally from Dr. Geoffrey Cooper (Boston University) and were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% calf serum (Colorado Calf Serum).
Mouse embryonic fibroblasts devoid of endogenous Ras alleles
(Rasless MEFs) were obtained from Dr. Mariano Barbacid
(CNIOMadrid) and weremaintained in DMEM supplemented
with 10% calf serum (22).
Rasless MEF Growth—Primary mouse embryonic fibroblast
(MEFs; DU315) devoid of all endogenous RAS protein expres-
sion (Hras/; Nras/; Kraslox/lox; RERTert/ert) were gener-
ated and characterized previously (22) and were obtained from
Dr. Mariano Barbacid (CNIO, Madrid, Spain). In brief, DU315
cells were treated with 600 nM 4-hydroxytamoxifen to activate
translocation of the estrogen receptor-fused Cre to the nucle-
us for removal of the endogenous (floxed) Kras. Cells were
arrested in the G1 phase after 9–11 days. Blot analyses were
done to verify loss of endogenous KRAS protein expression.
Cell proliferation resumed after the delivery of a KRAS trans-
gene to the cells using lentiviral transduction. Transduced cells
were selected using blasticidin and expanded to generate cell
line pools dependent on expression of the exogenous transgene
for continuous proliferation.
Anchorage-dependent Growth Assays—To monitor prolifer-
ation rates, cells were plated onto a 96-well plate at a density of
2000 cells/well. After 24, 96, and 168 h, cell proliferation was
monitoredusingtheMTTcolorimetricviabilityassay,andabsor-
bance was measured at 550 nm to quantify cell number.
NIH 3T3 Infection—NIH 3T3 cells were infected with the
pBabe-puro retrovirus expression vectors containing cDNA
sequences encoding human KRAS4B (WT, K104Q, 12V, and
12V/K104Q). Post-infection, the cultures were maintained in
complete growth medium supplemented with puromycin to
select for stably infected cells. Samples were collected imme-
diately after 72 h post-selection and analyzed for signaling
via Western blotting. The drug-resistant cells were further
passaged and maintained in puromycin-containing growth
medium. Light microscopy images were collected at 24 h (Nikon
Eclipse TS100) post-selection tomonitor transformation.
RAS-GTP Pull-down Assays—NIH-3T3 cells were infected
with retrovirus containing cDNA for KRAS (WT, K104Q, 12V,
12V/K104Q), followed by selection in puromycin-containing
growth medium, to establish mass populations of drug-resist-
ant cells. Determination of the steady-state GTP-bound levels
of eachKRAS proteinwas performed using standard pull-down
analyses as described by us previously (44). Briefly, drug-resist-
ant mass populations of cells maintained in complete calf
serum-containing growth medium were collected 72 h post-
infection for analyses. The cultures were lysed in detergent
buffer, and the total cell lysates were then incubated with
recombinant glutathione S-transferase (GST)-tagged CRAF
RBD protein, followed by Protein G-Sepharose beads, to isolate
the bound KRAS-GTP. After separation by SDS-PAGE, the
level of KRAS-GTP was determined by blot analyses with anti-
KRAS antibody. Total FLAG epitope-tagged KRAS was deter-
mined by blot analyses with anti-FLAG antibody using the total
cellular lysate.
Retrovirus Production—Retrovirus was produced in HEK-
293T cells via transfection of pBABE-puro target vector and
pCL-10A1 packaging vector with calcium chloride. Cells were
allowed to produce retrovirus for 24 h. Retrovirus was then
harvested and placed on target cells in the presence of 2 g/ml
Polybrene. Cells were incubated with retrovirus for 8 h. Fresh
medium was then placed on the cells, and antibiotic selection
was applied 24 h later (2 g/ml puromycin).
Western Blotting—Cells maintained in complete growth
mediumwere lysed in 1%Nonidet P-40 buffer (50mMTris, 150
mMNaCl, 10 mMMgCl2, 10% glycerol, 1% Nonidet P-40, 0.25%
sodium deoxycholate, pH 7.4) and resolved using SDS-PAGE
analysis. To determine the levels of effector signaling, Western
blotting analyses were done using phospho-specific antibodies
to ERK1/2(Thr202/Tyr204) and AKT(Ser473), with antibodies
recognizing total ERK1/2 and AKT to control for total protein
expression (Cell Signaling Technologies). Antibodies for KRAS
(OP24, EMDMillipore) and anti-HA epitope (16B12, Covance)
were used to determine the expression levels of endogenous
and exogenous KRAS, respectively. An antibody for vinculin
(Sigma-Aldrich) was used to verify equivalent loading of cellu-
lar proteins.
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